Q32 Bio Inc QTTB.OQ QTTB.O is expected to show no change in quarterly revenue when it reports results for the period ending December 31 2024
LSEG's mean analyst estimate for Q32 Bio Inc is for a loss of $1.25 per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 19.0% in the last three months.
Wall Street's median 12-month price target for Q32 Bio Inc is 85.00, above its last closing price of $47.46.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -1.40 | -1.40 | -1.46 | Missed | -4 |
Jun. 30 0001 | -1.05 | -1.04 | -1.42 | Missed | -36.2 |
Mar. 31 2024 | -1.42 | -2.32 | -14.95 | Missed | -543.5 |
Dec. 31 2023 | -5.40 | -5.40 | -5.04 | Beat | 6.7 |
Jan. 1 0001 | -7.56 | -7.56 | -10.26 | Missed | -35.7 |
Jun. 30 2023 | -8.94 | -8.55 | -10.98 | Missed | -28.4 |
Jan. 1 0001 | -9.71 | -9.54 | -9.00 | Beat | 5.7 |
Jan. 1 0001 | -9.11 | -9.07 | -10.80 | Missed | -19.1 |
This summary was machine generated November 8 at 16:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)